NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 6 Issue 3 Page 197-202, 2025

©NIJSES PUBLICATIONS
Open Access

ONLINE ISSN:2992-5819
PRINT ISSN:2992-6149

https://doi.org/10.59298/NIJSES/2025/63.197202

Regulatory Frameworks for Emerging Medical Technologies

Mukisa Ian Mugaiga

Department of Pharmacology Kampala International University Uganda
Email:mugaiga.mukisa@studwc.kiu.ac.ug

ABSTRACT

The rapid evolution of emerging medical technologies, particularly those driven by artificial intelligence (AI), the Internet of Things (IoT), and big data, presents unprecedented opportunities and challenges for global healthcare systems. From wearable devices to surgical robots and voice conversational interfaces, these innovations are reshaping diagnosis, treatment, and patient engagement. However, the adaptive nature of these technologies, especially machine learning systems that evolve post-deployment, poses unique risks that traditional regulatory frameworks are ill-equipped to manage. This paper explores the need for dynamic, responsive, and ethical regulatory frameworks that ensure the safety, efficacy, and accountability of such medical devices without stifling innovation. Drawing on global case studies, evolving risk management approaches, post-market surveillance strategies, and ethical considerations, it underscores the importance of international collaboration and adaptive policymaking. Ultimately, effective regulation must balance technological advancement with patient safety and public trust in a rapidly digitizing medical landscape.

Keywords: Emerging Medical Technologies, Artificial Intelligence, Medical Devices Regulation, Post-Market Surveillance, Risk Management, Ethics in Healthcare, IoT in Medicine.

INTRODUCTION

The term “emerging medical technologies” refers to innovative medical devices that have recently been developed or are currently in development, such as wearable devices, smartphones, imaging systems, surgical robots, and outpatient hospital systems. To promote the development of new medical devices that utilize innovative technologies while guaranteeing safety and efficacy, regulators have established frameworks for the regulation of devices. Innovations in science and technology, such as the Internet of Things (IoT) and artificial intelligence (AI), have made it possible to use a vast quantity of previously fragmented personal health records as the big data of the human body for medical prognosis, diagnosis, and therapy. Based on medical big data obtained from network-connected medical devices (MDs), it is possible to predict an epidemic of an infectious disease and grasp the progression of dementia. Various AI algorithms capable of elaborately processing this big data to utilize it for prognosis, diagnosis, and therapy are under development, including filtering cardiovascular attack voices, assessing the progression of liver cancer by analyzing the time series of images, analyzing 24-hour time series of the number of daily steps to assess fatigue symptoms, and predicting health anomalies by analyzing electrocardiograms and heart rate variability. All these systems usually contain machine learning algorithms for the learning and training of dedicated AI using the clinical data, which are constantly updated as the knowledge of the learning result is accumulated. Thus, it is expected that these technologies will provide new possibilities through the development of MDs whose behavior can be continuously modified. Currently, the safety and efficacy of MDs with frequently modifiable behavior, such as those utilizing IoT and AI, are inadequately guaranteed due to the lack of regulatory procedures that cover them. Several initiatives are now in

discussion to establish a new regulatory framework covering these emerging MDs that aims to educate patients regarding the behavior of non-transparent medical AI and guarantee the safety and efficacy of IoT-based MDs that continuously change over time [1, 2].

Importance of Regulatory Frameworks

Emerging medical technologies leverage artificial intelligence (AI) and real-time connectivity. Such innovations have the potential to radically change the provision of treatment and care across various fields, from robotic surgery to remote monitoring and care delivery. The very nature of medical devices (MDs) is changing, which brings new challenges that must be addressed in the future development of regulatory frameworks. The behavior of AI-driven learning MDs (hereafter "MDs") will differ in each clinical situation due to a difference in input data. In addition, the clinical situation will change even for predetermined artificial intelligence (AI) MDs. Thus, these MDs will modify their behavior in a variety of ways across diverse clinical situations. Effective monitoring to ensure the quality of learning and/or predetermined AI MDs should be established. A quality management system (QMS) for MDs is required to ensure the maintenance of the safety and efficacy of such MDs. In Japan, a quality management system (QMS) for MDs is proposed to ensure the maintenance of safety and efficacy of such AI-driven MDs. The marketing authorization holder (MAH) will provide a standard protocol for the collection of learning data and the QMS of the MDs. The proposed QMS will be similar to accepted QMS for traditional MDs, which is managed by the MAH, a hospital clinical engineer, system integrators, and MD designers. A hospital clinical engineer in charge of the MDs should monitor the operation and status of the MDs. In addition, the safety and efficacy of learning data collection during the use of MDs must be ensured. Thus, system integrators and MD designers are primarily responsible for the safe operation of the AI-driven MDs [3, 4].

Global Regulatory Landscape

Global regulatory frameworks are urgently and critically needed to effectively guide not just manufacturers and developers, but also health authorities and patients on the safe and secure use and innovative development of AI/ML-enabled health technologies. The current scenario presents a considerable and concerning temporal lag that is increasingly associated with an exponentially growing industry, which is evolving at an unprecedented pace. This particular industry is characterized by high buyer mobility and intense competition, making it essential to consider that the standardization of its various technologies demands a broad consensus among a diverse range of stakeholders. Additionally, safeguarding the public from potential AI-related harms and risks is not merely a necessity but rather an important and necessary extension of their traditional roles in regulatory policymaking. In this evolving context, it is paramount that comprehensive policies are established and implemented to address the multifaceted challenges posed by the rapid advancement and integration of such technologies, ensuring that public safety remains a top priority while simultaneously allowing for innovation to continue to flourish and thrive within these complex dynamics [5, 6].

Risk Assessment and Management

Health care technologies carry inherent risks, defined as the severity of adverse events multiplied by their likelihood. To meet US FDA and EU-MDR regulations, it is crucial to identify product hazards, estimate risks, and develop mitigation strategies. Risks linked to devices for home health monitoring have been identified, leading to proposed control strategies to bring these risks to acceptable levels. Regulatory submissions necessitate foundational tasks like assembling a design history file, conducting verification and validation tests, and performing clinical evaluations. Establishing compliance involves safety and effectiveness assessments; safety differs from reliability. Reliability refers to the continuous, malfunction-free performance of a device, influenced by design and quality assurance. In contrast, safety encompasses the likelihood and severity of injury-producing events, integral to product design. By defining acceptable risks and creating a risk management process, devices can be proven safe despite imperfections. To ensure products meet regulatory standards, risk management analysts create a risk score map, plotting system properties against a score of 1 to 5, where 1 signals acceptability. Each system component's risk score is assigned via a manual markup process. Regulatory agencies like the US FDA and European Notified Bodies mandate premarket assessments to ensure patient safety and device effectiveness. However, many stakeholders view regulations as overly burdensome and detrimental to innovation, as prescriptive regulations may lock in existing device methodologies and stifle new technology adoption [7, 8].

Clinical Trials and Evidence Generation

On May 26th, 2021, the new Medical Devices Regulation 2017/745 came into force in the European Union. At its core, it aims to provide a regulatory framework for medical devices that ensures a high level

of protection of health and safety, whilst supporting the internal market for medical devices. This includes ensuring the free movement of devices that are safe and comply with the regulation. In the context of Regulation (EU) 2017/745, the term medical devices covers a broad array of 'technologies' that may be regulated as a medical device. Importantly, the word technology is used in the broadest sense to incorporate physical devices such as implants and surgical instruments, as well as in vitro diagnostic tests, data and software technologies, and procedural technologies encompassing regenerative medicine and biovigilance. On the 15th of November 2018, the European Union ruled that the clinical investigation and evaluation of medical devices focused on implantable infusion pumps and other devices was insufficient to demonstrate compliance with the new logics of the Medical Devices Regulation. Subsequently, the Chief Medical Officer of the UK promised to do a high-level review of all higher-risk medical devices in use in the country. The goal of the review was not the limited remediation of one particular type of device but to create a series of principles intended to inform regulators and provide reassurance to patients and healthcare professionals about the process by which higher risk devices were investigated, certified and brought to market assurance in how the devices have been investigated, evaluated and manufactured. The background to this review was a long-standing lack of trust in medical devices resulting from serious incidents, poor guidance to regulators and healthcare professionals, and perceived industry influence on regulatory processes [9, 10].

Post-Market Surveillance

Emerging Medical Technologies (EMTs) offer innovative treatments but come with risks, especially post-launch. To promote uptake, innovators often provide free training and support to clinics. However, the complexity of these technologies can lead to uncertainty about their efficacy and safety. Health authorities may need to intervene if harmful technologies are used without proper monitoring. This discussion will cover the ethical and practical considerations behind decisions to withdraw technologies, while addressing challenges like disputed efficacy that complicate regulation. In Europe, a major overhaul of medical device regulation is underway, impacting safety assessments. Limited devices have been reviewed under the new Medical Device Regulation (MDR), raising safety concerns. The US and Europe show differing responses to safety signals, highlighting the need for a structured approach to off-label use until robust reporting and accountability systems are established. Measures introduced may also apply to non-medical technologies in health care. If a technology appears harmful, health organizations should first seek user feedback to mitigate risks. If such efforts fail, ensuring device safety becomes crucial until more evidence regarding effectiveness or public health crises emerges. As a last resort, authorities may need to publicly debate and limit the use of technologies deemed unsafe [11, 12].

Ethical Considerations in Regulation

The rapid breakthroughs in the development of Artificial Intelligence (AI) technologies have spurred the emergence of new ethical challenges, prompting discussions about how to uphold basic ethical principles. The goal of regulation is to protect the public interest, especially the most vulnerable groups, by avoiding the harms associated with the deployment of AI-based products and services. AI regulation is still in its infancy, despite rapid advancements in AI technologies and their wider adoption and deployment in sensitive areas such as healthcare. In the most recent years, physicians, university professors, patients, AI developers, technological platforms, software companies, and big tech firms have raised public alarms about fundamental ethical issues surrounding AI in healthcare. Existing frameworks, initially developed before the advent of AI, are expected to be rethought in light of the new ethical dilemmas, or new frameworks tailored to the medical domain are proposed. The incessant technological race allows only time-limited answers that might not be satisfactory in the long run. To avoid "the fog of suspicion" surrounding AI in healthcare, it is necessary to scrutinize the arguments advanced so far, identify gaps, and look for future avenues of research. Ethical–legal issues surrounding AI in medicine are presented in three clusters: general issues, whose relevance extends beyond the healthcare domain; issues primarily affecting the healthcare ecosystem; and issues specific to medical AI, with a focus on novel ethical–legal considerations. Reference is made to a few examples of concrete proposals or lessons learned for solving the issues raised. It is paramount to respond to the growing calls for a legal and ethical framework that combines the best features of existing ethical and legal solutions and contextualizes them in the medical domain. To spur further discussions, the future avenues of research on ethical governance principles, the need for international dialogue on patient data, greater scrutiny of AI functionalities and limitations, and the need for personal dimensions are outlined [13, 14].

Case Studies of Emerging Technologies

a. Cosmetic and Fulfillment Robotic Technologies for Elderly Care and Loneliness Prevention
Companionship robot systems are increasingly being developed to actively support and provide companionship for the elderly population. These innovative robots are designed with a variety of functions, ranging from simple reminder messages to engaging video chats and even virtual pets. Each system has distinct designs and objectives that reflect the diverse capabilities they offer. In compliance states such as "care" or "service," these robotic devices synthesize multi-modal messages derived from observed user states, enabling them to respond appropriately to the needs of their users. However, current systems are facing significant limitations in their selection rules and responses, which underscores a pressing need for the development of semi-autonomous robots. Such advancements would address a wider spectrum of user needs and enhance the overall interaction experience. Additionally, the diversity of robotic companions poses important ethical concerns regarding the treatment and dignity of elderly individuals, necessitating ongoing discussions and considerations in robotics design.

b. Voice Conversational Interface (VCI) Technologies for Medical Information Support
A Voice Conversational Interface (VCI) system is being specifically developed for elderly individuals who are living alone, in alignment with the broader Smart Aging initiatives. This innovative system integrates standard VCI components with proprietary technologies, allowing it to address a wide range of health-related inquiries while also providing crucial medication guidance. The design of the system emphasizes the importance of maintaining a smooth conversational flow, which is essential for establishing context during interactions with users. Furthermore, great care has been taken to create an elder-friendly interface tailored for health informatics systems that leverages voice conversation. The anticipated impact on the elderly community is expected to be profoundly significant, improving access to medical information and support, thus contributing to better health outcomes and enhanced quality of life for elderly individuals [15, 16].

Challenges in Regulatory Approaches

Despite the wide variety of emerging health technologies with distinct characteristics, regulators commonly face similar questions and challenges regarding the use of new technologies for the first time in health interventions or programs. Even prior to the COVID-19 pandemic, emerging technologies were rapidly proliferating and raising questions for health systems, often outpacing regulators' agility. The pandemic's impact on people's behaviours, policies, testing methods, and assets, along with the urgency to develop treatments, brought new uncertainties regarding the safety and efficacy of already-regulated tools. Understanding how countries have approached the regulation of a specific new intervention or event of concern can help identify regulatory questions and considerations; it can be used as a reference for technologies that are new in one location but more established elsewhere. This reflects scenarios where health technologies that are established and approachable in certain countries are increasingly enticing for adoption in middle- and low-income countries, but come with new regulatory issues. Understanding what they are and how equivalent technologies were regulated elsewhere can guide the development of a country's initial approach for a new health technology. Several countries faced a dilemma when assessing the appropriateness of available vaccines for COVID-19, specifically those that were newly developed and approved outside the country's jurisdiction but had not yet been implemented via a national campaign. Countries with few or no vaccines were in a rush and had little time for extensive evaluation, but uptake of an inappropriate product was perhaps worse than no vaccination at all. The urgency associated with the COVID-19 vaccine acquisition scenario presents the latest developments of pandemic preparedness. Regardless of a country's health system and vaccination landscape, specific considerations, such as availability of background data, establishment of external quality assessment mechanisms, validation needs, and alternative assessments arose [17, 18].

Future Directions in Regulation

This paper explores the shifts in climate and regulatory factors affecting emerging medical technologies, particularly AI software in MedTech. It focuses on the evolving regulatory landscape in the US and Europe, where initial frameworks are being developed, while acknowledging global activities for future analysis. The end of the COVID-19 Health Emergency Declaration has significantly influenced the adoption of established and emerging technologies. The pandemic accelerated the development of many AI software programs without pre-market entry or post-market scrutiny, leading to ambiguity around patient rights, health inequities, care availability, and ethical considerations in healthcare algorithms. Additionally, recent legislation, including the European AI Act and US frameworks for AI risk management and supply chain, has started implementation, addressing AI across various sectors and

emphasizing product quality assurance, algorithm transparency, and governance accountability. Public discussions on the implications of generative AI models are ongoing, with concerns regarding hallucination risks, biased outputs from inadequate training, lack of transparency, and the impact on workflow and accountability [19-23].

CONCLUSION

As the integration of AI, IoT, and other cutting-edge technologies continues to redefine healthcare, regulatory frameworks must evolve in tandem to safeguard public health while supporting innovation. Existing regulatory systems often lag behind technological advancement, creating uncertainty in ensuring the safety and efficacy of adaptive, data-driven medical devices. It is essential to develop agile, risk-based, and ethically grounded frameworks that incorporate real-time learning, transparent clinical validation, robust post-market surveillance, and patient-centered accountability. Regulatory harmonization across nations, coupled with collaboration among stakeholders including developers, clinicians, patients, and policymakers, will be pivotal in addressing the global challenges presented by emerging medical technologies. With clear governance structures, ethical foresight, and dynamic oversight, regulatory bodies can successfully navigate the complexities of this transformative healthcare era.

REFERENCES

1. Amaral C, Paiva M, Rodrigues AR, Veiga F, Bell V. Global regulatory challenges for medical devices: impact on innovation and market access. Applied Sciences. 2024 Oct 12;14(20):9304.
2. Teli MS, Jhawat V, Sharma AK. Development of a Comprehensive Regulatory Model for Medical Devices. BIO Integration. 2024 Oct 1;5(1):972.
3. Sadhu PK, Yanambaka VP, Abdelgawad A, Yelamarthi K. Prospect of internet of medical things: A review on security requirements and solutions. Sensors. 2022 Jul 24;22(15):5517. mdpi.com
4. Badnjevic A. Evidence-based maintenance of medical devices: Current shortage and pathway towards solution. Technology and Health Care. 2023 Jan;31(1):293-305.
5. Kaladharan S, Manayath D, Gopalakrishnan R. Regulatory challenges in AI/ML-enabled medical devices: A scoping review and conceptual framework. Journal of Medical Devices. 2024 Dec 1;18(4). [HTML]
6. Maresova P. Impact of Regulatory Changes on Innovations in the Medical Device Industry: Comment on" Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It?-A Viewpoint Paper". International journal of health policy and management. 2022 Jun 15;12:7262.
7. Maresova P, Rezny L, Peter L, Hajek L, Lefley F. Do regulatory changes seriously affect the medical devices industry? Evidence from the Czech Republic. Frontiers in public health. 2021 Apr 28;9:666453.
8. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. Medicine. 2024 Jul 12;103(28):e38834.
9. Salisbury JP. Using medical device standards for design and risk management of immersive virtual reality for at-home therapy and remote patient monitoring. JMIR biomedical engineering. 2021 Jun 3;6(2):e26942.
10. Maresova P. Impact of Regulatory Changes on Innovations in the Medical Device Industry: Comment on" Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It?-A Viewpoint Paper". International journal of health policy and management. 2022 Jun 15;12:7262. nih.gov
11. Kondrath S, Maddi R. Technical documentation requirements for medical devices approval in the European Union and a detailed emphasis on air-way products. Journal of Innovations in Applied Pharmaceutical Science (JIAPS). 2021 Oct 18:48-53. saapjournals.org
12. Kruachottikul P, Tea-makorn P, Dumrongvute P, Hemrungrojn S, Nupairoj N, Junchaya O, Vinayavekhin S. MediGate: a MedTech product innovation development process from university research to successful commercialization within emerging markets. Journal of Innovation and Entrepreneurship. 2024 Oct 10;13(1):71. springer.com
13. Haynes G. Post launch physician relationships. InInnovation Anesthesiology 2024 Jan 1 (pp. 363-389). Academic Press.
14. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Sustainable development goals (SDGs) and resilient healthcare

systems: Addressing medicine and public health challenges in conflict zones. Medicine. 2025 Feb 14;104(7):e41535.
15. De Almeida PG, dos Santos CD, Farias JS. Artificial intelligence regulation: a framework for governance. Ethics and Information Technology. 2021 Sep;23(3):505-25. researchgate.net
16. Kaminski ME. Regulating the Risks of AI. BUL Rev.. 2023;103:1347.
17. Chen C, Johnson JG, Charles K, Lee A, Lifset ET, Hogarth M, Moore AA, Farcas E, Weibel N. Understanding barriers and design opportunities to improve healthcare and QOL for older adults through voice assistants. InProceedings of the 23rd International ACM SIGACCESS Conference on Computers and Accessibility 2021 Oct 17 (pp. 1-16). acm.org
18. Sin J, Munteanu C, Ramanand N, Tan YR. VUI influencers: How the media portrays voice user interfaces for older adults. InProceedings of the 3rd Conference on Conversational User Interfaces 2021 Jul 27 (pp. 1-13). jaisiesin.com
19. Zakerabasali S, Ayyoubzadeh SM, Baniasadi T, Yazdani A, Abhari S. Mobile health technology and healthcare providers: systemic barriers to adoption. Healthcare Informatics Research. 2021 Oct 31;27(4):267-78. koreamed.org
20. Paul-Chima UO, Ugwu CN, Alum EU. Integrated approaches in nutraceutical delivery systems: optimizing ADME dynamics for enhanced therapeutic potency and clinical impact. RPS Pharmacy and Pharmacology Reports. 2024 Oct;3(4):rqae024.
21. Ziebland S, Hyde E, Powell J. Power, paradox and pessimism: on the unintended consequences of digital health technologies in primary care. Social Science & Medicine. 2021 Nov 1;289:114419.
22. Ali H. AI for pandemic preparedness and infectious disease surveillance: predicting outbreaks, modeling transmission, and optimizing public health interventions. Int J Res Publ Rev. 2024 Aug;5(8):4605-19.
23. Aderamo AT, Olisakwe HC, Adebayo YA, Esiri AE. AI-powered pandemic response framework for offshore oil platforms: Ensuring safety during global health crises. Comprehensive Research and Reviews in Engineering and Technology. 2024;2(1):044-63. crrjournals.com

CITE AS: Mukisa Ian Mugaiga (2025). Regulatory Frameworks for Emerging Medical Technologies. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 6(3):197-202 https://doi.org/10.59298/NIJSES/2025/63.197202